Impact of vitamin D supplementation on cardio-metabolic status and androgen profile in women with polycystic ovary syndrome: placebo-controlled clinical trial

Rashad, Nearmeen M.; Abd El-Fatah, Azza H.; Lashin, Mohamed El-Bakry; Abomandour, Hala G.; Allam, Reem M.

doi:10.1186/s43043-019-0005-y

Middle East Fertility Society Journal

Table 3 The impact of vitamin D supplementations on cardio-metabolic status and androgenic profile in PCOS group

From: Impact of vitamin D supplementation on cardio-metabolic status and androgen profile in women with polycystic ovary syndrome: placebo-controlled clinical trial

	Non-intervention group (n = 40)			Intervention group (n = 55)
	Before	After	P value	Before	After	P value
BMI (kg/m²)	23.72 ± 2.34	26.37 ± 4.84	˂ 0.001*	33.43 ± 3.96	26.8 ± 5.74	˂ 0.001*
Waist/hip ratio	1.07 ± .196	1.124 ± 0.19	0.341	1.491 ± .32113	1.147 ± 0.180	˂ 0.001*
SBP (mmHg)	113.8 ± 3.59	116.4 ± 5.26	0.050	123.1 ± 6.6	116.8 ± 7.02	˂ 0.001*
DBP (mmHg)	71.05 ± 8.23	72.72 ± 7.29	0.314	77.47 ± 7.50	69.27 ± 6.77	˂ 0.001*
Hirsutism score	6.35 ± 0.90	6.50 ± 0.78	0.839	11.83 ± 3.86	9.4 ± 4.50	˂ 0.001*
Ovarian volume	13.61 ± 1.80	13.99 ± 1.72	0.536	18.31 ± 3.697	13.58 ± 2.80	˂ 0.001*
AFC	12.31 ± 1.80	12.69 ± 1.72	0.575	20.5 ± 3.69	13.36 ± 3.68	˂ 0.001*
T. cholesterol (mg/dL)	175.5 ± 11.4	186.9 ± 22.66	˂ 0.05*	232.3 ± 20.9	203.2 ± 31.6	˂ 0.001*
Triglycerides (mg/dL)	164.4 ± 20.9	168.6 ± 27.3	0.617	232.3 ± 57.3	198.6 ± 25.01	˂ 0.001*
LDL .C(mg/dL)	94.86 ± 17.1	108.1 ± 25.8	˂ 0.05*	148.7 ± 16.1	119.5 ± 31.63	˂ 0.001*
HDL .C(mg/dL)	47.5 ± 3.36	45.12 ± 4.97	˂ 0.05*	37.14 ± 5.18	44.01 ± 5.338	˂ 0.001*
FPG (mg/dL)	86.05 ± 4.77	87.47 ± 4.21	0.057	89.38 ± 2.38	88.29 ± 1.74	˂ 0.001*
FSI (μU/mL)	6.1 ± 0.83	7.74 ± 4.02	0.140	16.5 ± 6.108	12.28 ± 5.251	˂ 0.001*
HOMA-IR	1.31 ± 0.23	1.67 ± 0.91	0.111	3.61 ± 1.287	2.67 ± 1.15	˂ 0.001*
HOMA-β	98.2 ± 13.1	113.5 ± 50.72	0.332	231.3 ± 98.1	174.8 ± 73.6	˂ 0.001*
T.testosterone (ng/mL)	0.605 ± 0.33	0.62 ± 0.29	0.789	0.93 ± 0.35	0.88 ± 0.34	˂ 0.001*
SHBG (nmol/L)	48.8 ± 17.1	45.65 ± 18.52	0.390	26.5 ± 17.14	32.25 ± 13.07	0.067
DHEA-S (μg/dl))	171.2 ± 49.6	169.4 ± 48.6	0.908	276.4 ± 79.77	209.7 ± 80.51	˂ 0.001*
Androstenedione (ng/mL)	3.3 ± 1.94	3.55 ± 1.83	0.626	3.45 ± 2.196	1.42 ± 0.404	0.440
FSH (mIU/mL)	9.1 ± 0.15	8.96 ± 0.156	0.451	8.54 ± 0.27	8.08 ± 0.403	˂ 0.001*
LH (mIU/mL)	9.6 ± 1.4	9.6 ± 1.19	0.954	12.8 ± 3.153	9.69 ± 0.66	˂ 0.001*
LH/FSH	1.07 ± 0.16	1.07 ± 0.13	0.965	1.13 ± 0.098	1.6 ± 0.42	˂ 0.001*
25(OH)-D (ng/ml)	15.32 ± 1.085	14.55 ± 1.60	0.383	10.9 ± 2.469	26.6 ± 6.64	˂ 0.001*
Ca (mg/dl)	8.14 ± 0.83	8.31 ± 0.831	0.404	8.17 ± 0.87	8.26 ± 1.01	0.607
PO4 (mg/dl) (mg/dl	5.43 ± 0.5	5.54 ± 0.55	0.404	5.44 ± 0.58	5.5 ± .674	0.883
ALP (U/L)	100.7 ± 13.5	106.5 ± 16.26	0.142	163.9 ± 18.5	127.1 ± 19.9	˂ 0.001*
WBC count (cell × 103/μl)	5.03 ± 0.934	5.65 ± 1.45	˂ 0.001*	8.70 ± 0.66	7.50 ± 0.945	˂ 0.001*
Neutrophil count (cell × 10³/μl)	2.71 ± 0.668	3.1 ± 0.9	˂ 0.001*	4.72 ± 0.661	4.17 ± 0.702	˂ 0.001*
hs-CRP (μg/ml)	4.6 ± 0.668	4.9 ± 0.97	˂ 0.001*	6.6 ± 0.661	6.0 ± 0.70	˂ 0.001*
CIMT(mm)	1.25 ± 0.093	1.29 ± 0.112	0.142	1.689 ± 0.127	1.440 ± 0.13	˂ 0.001*

*Statistically significant (P < 0.05)

Back to article page